The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration--a phase IV randomised clinical trial with ranibizumab: the FLUID study

Jennifer J Arnold, Caroline M Markey, Nicol P Kurstjens, Robyn H Guymer, Jennifer J Arnold, Caroline M Markey, Nicol P Kurstjens, Robyn H Guymer

Abstract

Background: With increasing experience using anti-VEGF therapy for the treatment of neovascular age-related macular degeneration (nAMD), ophthalmologists have shifted away from a "one size fits all" to an "individualised" approach based on disease activity with the aim of achieving a fluid-free retina. The FLUID study investigates the non-inferiority of a Treat and Extend (T&E) protocol of 0.5 mg ranibizumab, which allows treatment extension in the presence of incomplete resolution of sub-retinal fluid (SRF) ≤200 μm at the foveal centre relative to a T&E protocol that requires complete resolution of all retinal fluid (i.e., both SRF and intra-retinal fluid [IRF]) in patients with nAMD.

Methods/design: This 24 month, randomised, phase IV trial has completed recruitment of treatment-naïve patients randomised 1:1 to ranibizumab "intensive" treatment (complete resolution of IRF and SRF) or ranibizumab "relaxed" treatment (resolution of IRF or >200 μm SRF only at foveal centre). Patients in both arms follow a T&E regimen where extension decisions are based upon assessment of lesion activity: loss of ≥5 letters of visual acuity, new haemorrhage, presence of IRF and SRF on an optical coherence tomography (OCT) scan. The determination of SRF is conducted at a reading centre while the assessment of IRF is physician-determined. The primary endpoint is the mean change in best-corrected visual acuity (BCVA) from baseline to 24 months. Secondary endpoints include the mean change in central retinal thickness (CRT) from baseline to 12 and 24 months, the number of ranibizumab injections administered at 12 and 24 months, and the pharmacogenomic assessment of AMD Gene Consortium-identified single-nucleotide polymorphisms (SNPs) and their association with treatment response. Three hundred and forty seven (347) patients have been recruited by 16 Australian sites within approximately 16 months. A protocol to adjudicate on SRF has been established by the central reading centre and is demonstrating good concordance with investigator assessment.

Discussion: This study will provide important insights into retreatment criteria for managing nAMD using a T&E regimen. The current paper describes the clinical rationale for using a less intensive treatment approach using ranibizumab and details of the treatment protocol.

Trial registration number: NCT01972789. Date of registration: 24th October 2013.

Keywords: Intra-retinal fluid; Neovascular AMD; Ranibizumab; Sub-retinal fluid; Treat and extend regimen.

Figures

Fig. 1
Fig. 1
OCT image showing presence of SRF (

Fig. 2

Flow chart outlining patient enrollment…

Fig. 2

Flow chart outlining patient enrollment and allocation for study

Fig. 2
Flow chart outlining patient enrollment and allocation for study
Fig. 2
Fig. 2
Flow chart outlining patient enrollment and allocation for study

References

    1. Deloitte Access Economics. Eyes on the future: A clear outlook on age-related macular degeneration. Macular Degeneration Foundation. 2011. Available at . Accessed 15 March 2016.
    1. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31. doi: 10.1056/NEJMoa054481.
    1. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, et al. ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR Study. Ophthalmology. 2009;116:57–65. doi: 10.1016/j.ophtha.2008.10.018.
    1. Novartis Pharmaceuticals Australia . Lucentis Australian Prescribing Information. 2011.
    1. Eldem MB, Bartz-Schmidt KU, Schlingemann RO, Guymer R, Axer-Siegel R, on behalf of the EXCITE study group. Visual acuity response profiles in patients with neovascular age-related macular degeneration treated quarterly with ranibizumab in the EXCITE trial. Invest Ophthalmol Vis Sci. 2009;50:2374.
    1. Frampton JE. Ranibizumab: A review of its use in the treatment of neovascular age-related macular degeneration. Drugs Aging. 2013;30:331–58. doi: 10.1007/s40266-013-0077-9.
    1. Holz FG, Korobelnik JF, Laznetta P, Mitchell P, Schmidt-Erfurth U, Wolf S, et al. The effects of a flexible visual acuity-driven regimen in age-related macular degeneration: outcomes of a drug and disease model. Invest Ophthalmol Vis Sci. 2010;51:405–12. doi: 10.1167/iovs.09-3813.
    1. Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, et al. SUSTAIN Study Group. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology. 2011;118:663–71. doi: 10.1016/j.ophtha.2010.12.019.
    1. Kovach JL, Schwartz SG, Flynn HW, Jr, Scott IU. Anti-VEGF treatment strategies for wet AMD. J Ophthamol. 2012;2012:786870.
    1. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular agerelated macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148:43–58. doi: 10.1016/j.ajo.2009.01.024.
    1. CATT Research Group. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897–908. doi: 10.1056/NEJMoa1102673.
    1. CATT Research Group. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE. Ranibizumab and bevacizumab for treatment of neovascular age-related Macular degeneration. Two-year results. Ophthalmology. 2012;119:1388–98. doi: 10.1016/j.ophtha.2012.03.053.
    1. Busbee BG, Ho AC, Brown DM, Heier JS, Suner IJ, Li Z, et al. the HARBOR study Group. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120:1046–56. doi: 10.1016/j.ophtha.2012.10.014.
    1. Gupta OP, Shienbaum G, Patel AH, Fecarotta C, Kaiser RS, Regillo CD. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2010;117:2134–40. doi: 10.1016/j.ophtha.2010.02.032.
    1. Oubraham H, Cohen SY, Samimi S, Marotte D, Bouzaher I, Bonicel P, et al. Inject and extend dosing versus dosing as needed. A comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina. 2011;31:26–30. doi: 10.1097/IAE.0b013e3181de5609.
    1. Toalster N, Russell M, Ng P. A 12-month prospective trial of inject and extend regimen for ranibizumab treatment of age-related macular degeneration. Retina. 2013;33:1351–8. doi: 10.1097/IAE.0b013e3182831265.
    1. Abedi F, Wickremasinghe S, Islam AFM, Inglis KM, Guymer RH. Anti-VEGF treatment in neovascular age-related macular degeneration. A treat-and-extend protocol over 2 years. Retina. 2014;34:1531–8. doi: 10.1097/IAE.0000000000000134.
    1. Gianniou C, Dirani A, Ferrini W, Marchionno L, Decugis D, Deli A, et al. Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results. Eye. 2015;29:450–1. doi: 10.1038/eye.2014.321.
    1. Gillies MC, Walton RJ, Arnold JJ, McAllister IL, Simpson JM, Hunyor AP, et al. Comparison of outcomes from a phase 3 study of age-related macular degeneration with a matched, observational cohort. Ophthalmology. 2014;121:676–81. doi: 10.1016/j.ophtha.2013.09.050.
    1. Arnold JJ, Campain A, Barthelmes D, Simpson JM, Guymer RH, Hunyor AP, et al. Two-year outcomes of “treat and extend” intravitreal therapy for neovascular age-related macular degeneration. Ophthalmology. 2015;122:1212–1219. doi: 10.1016/j.ophtha.2015.02.009.
    1. Spaide R. Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol. 2007;143:679–80. doi: 10.1016/j.ajo.2007.02.024.
    1. Schmidt-Erfurth U, Kaiser P, Korobelnik JF, Brown DM, Chong V, Nguyen QD, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration. Ninety-six week results of the VIEW studies. Ophthalmology. 2014;121:193–201. doi: 10.1016/j.ophtha.2013.08.011.
    1. Grunwald JE, Daniel E, Huang J, Ying GS, Maquire MG, Toth CA, et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatment trials. Ophthalmology. 2014;121:150–61. doi: 10.1016/j.ophtha.2013.08.015.
    1. Brantley MA, Jr, Fang AM, King JM, Tewari A, Kymes SM, Shiels A. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology. 2007;114:2168–73. doi: 10.1016/j.ophtha.2007.09.008.
    1. Abedi F, Wickremasinghe S, Richardson AJ, Islam AF, Guymer RH, Baird PM. Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration. Ophthalmology. 2013;120:1641–8. doi: 10.1016/j.ophtha.2013.01.014.
    1. National Institute of Health Clinical Trials Registration Number. Accessed 15 March 2016.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する